Skip to main content

Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia

There are no specific drug therapies or vaccines for the pandemic of coronavirus disease 2019 (COVID-19), which is associated with substantial mortality. Attenuating or reversing the cytokine storm is critical for treating patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to have powerful immunoregulation and reparative properties in injured tissue with good safety [1]. This report aims to investigate whether umbilical cord MSC (UC-MSC) therapy improves the outcomes of 31 patients with severe or critical COVID-19 pneumonia.

We wish to report our experience using UC-MSCs for the treatment of severe COVID-19 pneumonia at Taikangtongji Hospital in Wuhan, China, from January 3, 2020, to April 4, 2020. Patient data, including demographics, clinical data, laboratory indices, treatment, and in-hospital outcomes, were collected. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) results of all patients were positive before UC-MSCs infused. Patients were diagnosed and treated according to national guidelines. Before the intravenous drip was established, UC-MSCs (1 × 106 cells per kilogram of weight) were suspended in 100 ml normal saline. We report numbers (percentages) for categorical variables and the median (interquartile range [IQR]) or mean ± standard deviation (SD) for continuous variables. Intergroup comparisons were performed with paired t tests.

We treated 31 COVID-19 patients with UC-MSCs. The median age was 70 years (IQR, 61–71 years); 25 patients (80.6%) were male. The proportion of treatment with oxygen was the highest (31 [100%]), followed by antivirals (26 [83.9%]), antibiotics (23 [74.2%]), intravenous immunoglobulin (8 [25.8%]), intravenous albumin (8 [25.8%]), and methylprednisolone (6 [19.4%]). The median (IQR) volume of infused UC-MSCs was 200 mL (100–300 mL). No adverse events were attributable to intravenous transplantation of UC-MSCs. After the first infusion of UC-MSCs, the SARS-CoV-2 PCR results of 30 patients (96.8%) became negative after a mean time of 10.7 days (SD, 4.2 days) (Table 1). Laboratory parameters tended to improve after UC-MSC therapy compared to the status before UC-MSC therapy, including elevated lymphocyte count (median [IQR], 1.09 [0.68–1.35] × 109/L vs 1.43 [1.02–2.20] × 109/L; P <  0.001), decreased C-reactive protein level (median [IQR], 13.39 [1.30–38.86] mg/L vs 0.50 [0.50–6.40] mg/L; P = 0.003), decreased procalcitonin level (median [IQR], 0.07 [0.05–0.09] ng/mL vs 0.04 [0.03–0.06] ng/mL; P <  0.001), decreased interleukin-6 level (median [IQR], 13.78 [5.69–25.26] pg/mL vs 4.86 [2.13–8.19] pg/mL; P <  0.001), decreased D-dimer level (median [IQR], 495 [320–727] ng/mL vs 288 [197–537] ng/mL; P = 0.010), and elevated PaO2/FiO2 (median [IQR], 242 [200–294] vs 332 [288–364]; P <  0.001) (Table 2).

Table 1 Baseline characteristics, treatments, and outcomes of patients with COVID-19 with UC-MSC therapy
Table 2 Comparison of laboratory parameters before and after UC-MSC therapy

Our experience showed that UC-MSC therapy may restore oxygenation and downregulate cytokine storms in patients hospitalized with severe COVID-19 without any infusion reaction. This approach is a promising candidate for the treatment of severe COVID-19 [2]. During the outbreak of COVID-19 in Wuhan, China, the number of patients increased sharply. However, the hospital capacity was limited, and many patients could not be admitted to the hospital. Hence, days between onset of symptoms and hospital admission were long. UC-MSCs can improve the lung microenvironment, pulmonary fibrosis, and lung function, probably due to the regulation of the inflammatory response and the promotion of tissue repair and regeneration [3]. A recent report of 7 patients found that bone marrow MSC therapy was an effective treatment for severe COVID-19 [3]. Moreover, another recent study indicated that bone marrow MSC therapy can improve hypoxia, immune reconstitution, and cytokine storms in patients with severe COVID-19 [4], which was consistent with our results. Further large multiple-center prospective trials are needed to confirm our results in the future.

Availability of data and materials

The data used to support the findings of this study are available from the corresponding author upon request.


  1. Galipeau J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824–33.

    Article  CAS  Google Scholar 

  2. Marini JJ, DeBacker D, Gattinoni L, Ince C, Martin-Loeches I, Singer P, Singer M, Westphal M, Vincent JL. Thinking forward: promising but unproven ideas for future intensive care. Crit Care. 2019;23(Suppl 1):197.

    Article  Google Scholar 

  3. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, et al. Transplantation of ACE2(−) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–28.

    Article  Google Scholar 

  4. Sengupta V, Sengupta S, Lazo AJ, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow Mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev. 2020.

Download references


We thank all the medical staff of Taikangtongji Hospital for the diagnosis and treatment of patients with COVID-19.



Author information

Authors and Affiliations



Concept and design: JW and ZG. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: JW and ZG. Critical revision of the manuscript for important intellectual content: JW. Statistical analysis: ZG. Administrative, technical, or material support: JW. Supervision: JW. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Jiang Wang.

Ethics declarations

Ethics approval and consent to participate

The Clinical Research Ethics Commissions of Taikangtongji Hospital approved the study and granted a waiver for the need to obtain written informed consent from the study participants as COVID-19 is an emerging infectious disease.

Consent for publication

Not applicable.

Competing interests

All authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, Z., Chen, Y., Luo, X. et al. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia. Crit Care 24, 420 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: